Compare CECO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CECO | BEAM |
|---|---|---|
| Founded | 1966 | 2017 |
| Country | United States | United States |
| Employees | 1600 | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | CECO | BEAM |
|---|---|---|
| Price | $67.77 | $26.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $67.67 | $46.00 |
| AVG Volume (30 Days) | 243.6K | ★ 2.1M |
| Earning Date | 02-24-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 334.15 | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $718,253,000.00 | $55,701,000.00 |
| Revenue This Year | $39.58 | N/A |
| Revenue Next Year | $14.60 | $23.55 |
| P/E Ratio | $49.57 | ★ N/A |
| Revenue Growth | ★ 29.86 | N/A |
| 52 Week Low | $17.57 | $13.53 |
| 52 Week High | $71.69 | $36.44 |
| Indicator | CECO | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 40.33 |
| Support Level | $66.66 | $27.00 |
| Resistance Level | $71.66 | $29.26 |
| Average True Range (ATR) | 2.61 | 2.24 |
| MACD | -0.29 | -0.74 |
| Stochastic Oscillator | 22.06 | 2.85 |
CECO Environmental Corp serves the energy, industrial, and other niche markets. The company operates through the Engineered Systems segment that serves the power generation, refinery, water/wastewater, and midstream oil and gas markets, and Industrial Process Solutions segment, which serves the broad industrial air pollution control, beverage can, fluid handling, electric vehicle production, food and beverage, semi-conductor, process filtration, pharmaceutical, petrochemical, wastewater treatment, wood manufacturing, desalination, and aquaculture markets. The majority of revenue is earned from the Engineered Systems Segment.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.